Cargando…

Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level

To evaluate clinical values of clinicopathologic and (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT)-related parameters for prediction of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in colorectal cancer (CRC) and to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jae-Hoon, Kang, Jeonghyun, Baik, Seung Hyuk, Lee, Kang Young, Lim, Beom Jin, Jeon, Tae Joo, Ryu, Young Hoon, Sohn, Seung-Kook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706250/
https://www.ncbi.nlm.nih.gov/pubmed/26735530
http://dx.doi.org/10.1097/MD.0000000000002236
Descripción
Sumario:To evaluate clinical values of clinicopathologic and (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT)-related parameters for prediction of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in colorectal cancer (CRC) and to investigate their variability depending on C-reactive protein (CRP) levels. In total, 179 CRC patients who underwent PET/CT scans before curative resection and KRAS mutation evaluation following surgery were enrolled. Maximum standardized uptake value (SUV(max)), peak standardized uptake value (SUV(peak)), metabolic tumor volume, and total lesion glycolysis were determined semiquantitatively. Associations between clinicopathologic and PET/CT-related parameters and KRAS expression were analyzed. Elevated CRP (>6.0 mg/L; n = 47) was associated with higher primary tumor size, higher SUV(max), SUV(peak), metabolic tumor volume, and total lesion glycolysis, compared with those for the group with a CRP lower than that the cutoff value (<6.0 mg/L; n = 132). Interestingly, the CRC patients (having CRP < 6.0 mg/L) with KRAS mutations had significantly higher (P < 0.05) SUV(max) and SUV(peak) values than the patients expressing wild-type KRAS mutations. Multivariate analysis revealed SUV(max) and SUV(peak) to be significantly associated with KRAS mutations (odds ratio = 3.3, P = 0.005, and odds ratio = 3.9, P = 0.004), together with histologic grade and lymph node metastasis. (18)F-FDG uptake was significantly higher in CRC patients with KRAS mutations and with normal CRP levels. A severe local inflammation with raised CRP levels, however, might affect accurate (18)F-FDG quantification in CRC tumors. Positron emission tomography/computed tomography-related parameters could supplement genomic analysis to determine KRAS expression in CRC; however, care should be exercised to guarantee proper patient selection.